Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00549874 · ClinicalTrials.gov registry record · NA
Effect of Rosiglitazone on Myocardial Blood Flow Regulation in Type 2 Diabetes
A NA study, sponsored by University of Michigan.
- Completed
- Registry status
- NA
- Development phase
- 27
- Enrollment target
NCT00549874 is a NA study that has completed, run by University of Michigan. The registered enrollment target is 27 participants.
The verdict
NCT00549874, a NA study, has completed, sponsored by University of Michigan.
- COMPLETED
- Registry status
- NA
- Development phase
- 27 participants
- Enrollment target
Study Summary
The overall hypothesis to be tested is that increased insulin resistance contributes to abnormal cardiac blood flow regulation in type 2 diabetic patients, which can be reversed by 6 months treatment with rosiglitazone. The planned experimental approach will be to utilize nuclear medicine techniques to evaluate whether the administration of rosiglitazone for 6 months can reverse regional deficits in myocardial blood flow and glucose utilization in type 2 diabetes in a randomized double blind controlled study. These studies will help elucidate the potential of rosiglitazone to correct deficits of myocardial blood flow complicating diabetes with the overall aim being the eventual prevention of sudden cardiac death.
Interventions
- DRUG Rosiglitazone
- DRUG Glyburide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2002-02 |
| Est. Completion | 2006-11 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00549874
The ClinicalTrials.gov registry entry for NCT00549874 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan, which has 1,327 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Rosiglitazone is the first listed.
NCT00549874 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00549874 about?
NCT00549874 is a clinical study titled "Effect of Rosiglitazone on Myocardial Blood Flow Regulation in Type 2 Diabetes". The overall hypothesis to be tested is that increased insulin resistance contributes to abnormal cardiac blood flow regulation in type 2 diabetic patients, which can be reversed by 6 months treatment with rosiglitazone. The planned experimental approach will be to utilize nuclear medicine techniques...
What is the current status of trial NCT00549874?
This trial is currently completed. It is a NA study. The enrollment target is 27 participants. The study started on 2002-02. Estimated completion is 2006-11.
What interventions are being tested in trial NCT00549874?
The interventions under investigation include: Rosiglitazone (DRUG), Glyburide (DRUG).
Who is sponsoring clinical trial NCT00549874?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.